Literature DB >> 15271889

Alpha 1-antitrypsin binds to and interferes with functionality of EspB from atypical and typical enteropathogenic Escherichia coli strains.

Sabine Knappstein1, Tina Ide, M Alexander Schmidt, Gerhard Heusipp.   

Abstract

Enteropathogenic Escherichia coli (EPEC), including diffusely adhering atypical E. coli, strains use a type III secretion system to deliver effector proteins into the membrane and cytoplasm of infected cells. The E. coli secreted proteins A, B, and D (EspA, EspB, and EspD) are required for the formation of the characteristic attaching and effacing (A/E) lesions. EspB and EspD are thought to form a translocation pore in the host cell membrane through which effector proteins are injected into the host cytosol. Besides its function in pore formation, EspB has been found in the cytosol and implicated to function as an effector protein. We screened for putative host cell proteins interacting with EspB of atypical EPEC strains and identified alpha(1)-antitrypsin (AAT) as a binding partner for EspB. AAT binds to EspB in pull-down and overlay experiments and also to EspD in overlay experiments. In agreement with the role of EspB and EspD in pore formation, EPEC-mediated hemolysis of red blood cells is strongly reduced by AAT in a concentration-dependent manner, indicating that AAT interferes with type III secretion by inhibiting the formation of the translocation pore. This is further supported by a decreased actin polymerization after infection of HeLa or CaCo-2 cells with EPEC in the presence of physiologically relevant concentrations of AAT. In this study, we identify AAT as a new binding partner for EspB and EspD, suggesting a previously unappreciated role for AAT in host cell defense against EPEC infections and potentially also against other bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271889      PMCID: PMC470586          DOI: 10.1128/IAI.72.8.4344-4350.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Role of EspF in host cell death induced by enteropathogenic Escherichia coli.

Authors:  J K Crane; B P McNamara; M S Donnenberg
Journal:  Cell Microbiol       Date:  2001-04       Impact factor: 3.715

2.  EspA filament-mediated protein translocation into red blood cells.

Authors:  R K Shaw; S Daniell; F Ebel; G Frankel; S Knutton
Journal:  Cell Microbiol       Date:  2001-04       Impact factor: 3.715

3.  Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function.

Authors:  B P McNamara; A Koutsouris; C B O'Connell; J P Nougayréde; M S Donnenberg; G Hecht
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

4.  A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells.

Authors:  S Knutton; I Rosenshine; M J Pallen; I Nisan; B C Neves; C Bain; C Wolff; G Dougan; G Frankel
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

5.  Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host mitochondria.

Authors:  B Kenny; M Jepson
Journal:  Cell Microbiol       Date:  2000-12       Impact factor: 3.715

6.  Citrobacter rodentium espB is necessary for signal transduction and for infection of laboratory mice.

Authors:  J V Newman; B A Zabel; S S Jha; D B Schauer
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Complete nucleotide sequence and analysis of the locus of enterocyte Effacement from rabbit diarrheagenic Escherichia coli RDEC-1.

Authors:  C Zhu; T S Agin; S J Elliott; L A Johnson; T E Thate; J B Kaper; E C Boedeker
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.

Authors:  L Shapiro; G B Pott; A H Ralston
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

9.  Role of EspB in experimental human enteropathogenic Escherichia coli infection.

Authors:  C O Tacket; M B Sztein; G Losonsky; A Abe; B B Finlay; B P McNamara; G T Fantry; S P James; J P Nataro; M M Levine; M S Donnenberg
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

10.  Type III secretion-dependent hemolytic activity of enteropathogenic Escherichia coli.

Authors:  J Warawa; B B Finlay; B Kenny
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

View more
  14 in total

Review 1.  Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation.

Authors:  Junkal Garmendia; Gad Frankel; Valérie F Crepin
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 2.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

3.  Interactions and predicted host membrane topology of the enteropathogenic Escherichia coli translocator protein EspB.

Authors:  Wensheng Luo; Michael S Donnenberg
Journal:  J Bacteriol       Date:  2011-04-15       Impact factor: 3.490

Review 4.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

5.  Analysis of the function of enteropathogenic Escherichia coli EspB by random mutagenesis.

Authors:  Wensheng Luo; Michael S Donnenberg
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 6.  Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.

Authors:  Ignacio Blanco; Beatriz Lara; Frederick de Serres
Journal:  Orphanet J Rare Dis       Date:  2011-04-12       Impact factor: 4.123

7.  Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia.

Authors:  Ignacio Blanco; Sabina Janciauskiene; Izabela Nita; Enrique Fernández-Bustillo; Victoriano Cárcaba; César Gallo; Marlene Alvarez-Rico; Frederick de Serres; Nana Béridze
Journal:  Clin Rheumatol       Date:  2009-11-19       Impact factor: 2.980

Review 8.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

9.  Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis.

Authors:  Qian Wang; Jianjun Du; Pengfei Yu; Bin Bai; Zhanwei Zhao; Shiqi Wang; Junjie Zhu; Quanxin Feng; Yun Gao; Qingchuan Zhao; Chaoxu Liu
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

10.  Structural basis of α-catenin recognition by EspB from enterohaemorrhagic E. coli based on hybrid strategy using low-resolution structural and protein dissection.

Authors:  Mitsuhide Hamaguchi; Hironari Kamikubo; Kayo N Suzuki; Yoshihisa Hagihara; Itaru Yanagihara; Ikuhiro Sakata; Mikio Kataoka; Daizo Hamada
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.